Department of Neurology, University Hospital Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
Neuro Oncol. 2017 Nov 29;19(12):1576-1587. doi: 10.1093/neuonc/nox112.
Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.
脑膜瘤是最常见的非神经胶质原发性脑肿瘤,约占脑肿瘤的 30%。通常,诊断和治疗计划主要基于神经影像学,主要使用 MRI 或很少使用 CT。最常见的治疗选择是神经外科切除和放疗(例如,放射外科、外部分次放疗)。治疗后随访使用 MRI 或 CT 等结构成像技术。然而,这些结构成像方式存在局限性,特别是在肿瘤描绘以及治疗后反应性变化的诊断方面。PET 等分子成像技术可以描述特定的代谢和细胞特征,这些特征可能提供超出单独使用结构 MRI 或 CT 成像获得的临床相关信息。目前,脑膜瘤患者中 PET 的使用正在稳步增加。在本文中,我们根据通过组织学或临床病程验证的研究得出的证据,为脑膜瘤的临床管理中使用 PET 成像提供了建议。